IGC Pharma Inc., a clinical-stage biopharmaceutical company focused on Alzheimer's disease, has announced the development of MINT-AD, a new AI-powered diagnostic platform. MINT-AD, short for Multimodal Interpretable Transformer for Alzheimer's, is designed to identify individuals at high risk of cognitive decline well before symptoms manifest. This platform aims to fill a critical gap in Alzheimer's diagnostics by providing physicians with a tool for early identification of high-risk patients. The company plans to launch a beta version of MINT-AD in Fiscal 2026 for pilot evaluation with academic and clinical partners. The results of these evaluations have not yet been presented, as the platform is still in development. The intended applications of MINT-AD include integration into electronic health records and web-based tools to support diagnostic processes and enhance patient stratification.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.